Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making

Overview

Journal J Pers Med

Date 2023 Nov 25

PMID 38003905

Authors

Alaa Fawaz

Alessandra Ferraresi

Ciro Isidoro

Affiliations

Soon will be listed here.

Abstract

Cancer is the second major cause of disease-related death worldwide, and its accurate early diagnosis and therapeutic intervention are fundamental for saving the patient's life. Cancer, as a complex and heterogeneous disorder, results from the disruption and alteration of a wide variety of biological entities, including genes, proteins, mRNAs, miRNAs, and metabolites, that eventually emerge as clinical symptoms. Traditionally, diagnosis is based on clinical examination, blood tests for biomarkers, the histopathology of a biopsy, and imaging (MRI, CT, PET, and US). Additionally, omics biotechnologies help to further characterize the genome, metabolome, microbiome traits of the patient that could have an impact on the prognosis and patient's response to the therapy. The integration of all these data relies on gathering of several experts and may require considerable time, and, unfortunately, it is not without the risk of error in the interpretation and therefore in the decision. Systems biology algorithms exploit Artificial Intelligence (AI) combined with omics technologies to perform a rapid and accurate analysis and integration of patient's big data, and support the physician in making diagnosis and tailoring the most appropriate therapeutic intervention. However, AI is not free from possible diagnostic and prognostic errors in the interpretation of images or biochemical-clinical data. Here, we first describe the methods used by systems biology for combining AI with omics and then discuss the potential, challenges, limitations, and critical issues in using AI in cancer research.

Citing Articles

AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis.

Alum E Discov Oncol. 2025; 16(1):313.

PMID: 40082367 PMC: 11906928. DOI: 10.1007/s12672-025-02064-7.

Relevance of proteomics and metabolomics approaches to overview the tumorigenesis and better management of cancer.

Singh P, Dhir Y, Gupta S, Kaushal A, Kala D, Nagraiik R 3 Biotech. 2025; 15(3):58.

PMID: 39949840 PMC: 11813842. DOI: 10.1007/s13205-025-04222-8.

An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway.

Pandey P, Lakhanpal S, Mahmood D, Kang H, Kim B, Kang S Front Pharmacol. 2025; 15():1513422.

PMID: 39834817 PMC: 11743680. DOI: 10.3389/fphar.2024.1513422.

Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways.

Situmorang P, Ilyas S, Nugraha S, Syahputra R, Nik Abd Rahman N Front Pharmacol. 2024; 15:1387866.

PMID: 39104398 PMC: 11298448. DOI: 10.3389/fphar.2024.1387866.

Joint Expedition: Exploring the Intersection of Digital Health and AI in Precision Medicine with Team Integration.

Giansanti D J Pers Med. 2024; 14(4).

PMID: 38673015 PMC: 11051462. DOI: 10.3390/jpm14040388.

References

Thiele I, Palsson B . A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protoc. 2010; 5(1):93-121. PMC: 3125167. DOI: 10.1038/nprot.2009.203. View

Ngiam K, Khor I . Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019; 20(5):e262-e273. DOI: 10.1016/S1470-2045(19)30149-4. View

Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi P, Wang Y . Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep. 2018; 23(1):255-269.e4. PMC: 5916795. DOI: 10.1016/j.celrep.2018.03.077. View

Creixell P, Reimand J, Haider S, Wu G, Shibata T, Vazquez M . Pathway and network analysis of cancer genomes. Nat Methods. 2015; 12(7):615-621. PMC: 4717906. DOI: 10.1038/nmeth.3440. View

Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque J . Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys. 1999; 43(1):57-66. DOI: 10.1016/s0360-3016(98)00351-4. View

Ali M, Khan S, Wennerberg K, Aittokallio T . Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach. Bioinformatics. 2017; 34(8):1353-1362. PMC: 5905617. DOI: 10.1093/bioinformatics/btx766. View

Sharifi-Noghabi H, Zolotareva O, Collins C, Ester M . MOLI: multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics. 2019; 35(14):i501-i509. PMC: 6612815. DOI: 10.1093/bioinformatics/btz318. View

Luo J, Pan M, Mo K, Mao Y, Zou D . Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma. Semin Cancer Biol. 2023; 91:110-123. DOI: 10.1016/j.semcancer.2023.03.006. View

Swanson K, Wu E, Zhang A, Alizadeh A, Zou J . From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell. 2023; 186(8):1772-1791. DOI: 10.1016/j.cell.2023.01.035. View

10.

Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins T, Pich O . The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023; 616(7957):534-542. PMC: 10115651. DOI: 10.1038/s41586-023-05729-x. View

11.

Ranjan B, Schmidt F, Sun W, Park J, Honardoost M, Tan J . scConsensus: combining supervised and unsupervised clustering for cell type identification in single-cell RNA sequencing data. BMC Bioinformatics. 2021; 22(1):186. PMC: 8042883. DOI: 10.1186/s12859-021-04028-4. View

12.

Hasin Y, Seldin M, Lusis A . Multi-omics approaches to disease. Genome Biol. 2017; 18(1):83. PMC: 5418815. DOI: 10.1186/s13059-017-1215-1. View

13.

Grossman R, Heath A, Ferretti V, Varmus H, Lowy D, Kibbe W . Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016; 375(12):1109-12. PMC: 6309165. DOI: 10.1056/NEJMp1607591. View

14.

Yokota K, Uchida H, Sakairi M, Abe M, Tanaka Y, Tainaka T . Identification of novel neuroblastoma biomarkers in urine samples. Sci Rep. 2021; 11(1):4055. PMC: 7892837. DOI: 10.1038/s41598-021-83619-w. View

15.

Zhang Y, Xiong S, Wang Z, Liu Y, Luo H, Li B . Local augmented graph neural network for multi-omics cancer prognosis prediction and analysis. Methods. 2023; 213:1-9. DOI: 10.1016/j.ymeth.2023.02.011. View

16.

Gu C, Kim G, Kim W, Kim H, Lee S . Current status and applications of genome-scale metabolic models. Genome Biol. 2019; 20(1):121. PMC: 6567666. DOI: 10.1186/s13059-019-1730-3. View

17.

Suhail Y, Cain M, Vanaja K, Kurywchak P, Levchenko A, Kalluri R . Systems Biology of Cancer Metastasis. Cell Syst. 2019; 9(2):109-127. PMC: 6716621. DOI: 10.1016/j.cels.2019.07.003. View

18.

Hu J, Li X, Hu G, Lyu Y, Susztak K, Li M . Iterative transfer learning with neural network for clustering and cell type classification in single-cell RNA-seq analysis. Nat Mach Intell. 2021; 2(10):607-618. PMC: 8009055. DOI: 10.1038/s42256-020-00233-7. View

19.

Zhang L, Lv C, Jin Y, Cheng G, Fu Y, Yuan D . Deep Learning-Based Multi-Omics Data Integration Reveals Two Prognostic Subtypes in High-Risk Neuroblastoma. Front Genet. 2018; 9:477. PMC: 6201709. DOI: 10.3389/fgene.2018.00477. View

20.

Savage R, Messenger M, Neal R, Ferguson R, Johnston C, Lloyd K . Development and validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic patients referred urgently from primary care: a diagnostic accuracy study. BMJ Open. 2022; 12(4):e053590. PMC: 8977764. DOI: 10.1136/bmjopen-2021-053590. View